<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179332</url>
  </required_header>
  <id_info>
    <org_study_id>CT032-ADO02</org_study_id>
    <nct_id>NCT03179332</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump</brief_title>
  <official_title>A Euglycaemic Clamp Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of a Bolus Dose of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® by an Insulin Pump</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, randomised, double-blind, three-period, complete cross-over trial
      comparing the pharmacokinetic and the pharmacodynamic properties of BioChaperone® insulin
      lispro and the two active comparators Fiasp® and Novorapid® when given as a bolus on top of
      basal delivery with an insulin pump in subjects with type 1 diabetes mellitus. Each subject
      will be randomly assigned to a treatment sequence consisting of 3 dosing visits during which
      the subject will receive the investigational products. In a euglycaemic clamp setting,
      subjects will be given a bolus dose of 0.15 U/kg body weight.

      Throughout the glucose clamp procedure, blood glucose will be stabilised at a target level of
      100 mg/dL by means of an intravenous infusion of glucose. Blood samples for pharmacokinetic
      assessment will be drawn at specified timepoints and glucose infusion rates and blood glucose
      concentrations will be recorded for pharmacodynamic assessment during the 10-hour clamp
      procedure after dosing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Actual">September 27, 2017</completion_date>
  <primary_completion_date type="Actual">September 27, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCGIR(0-60min)</measure>
    <time_frame>60 minutes</time_frame>
    <description>Baseline corrected area under the glucose infusion rate curve from 0 to 60 minutes after bolus administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCins(0-30min)</measure>
    <time_frame>30 minutes</time_frame>
    <description>Baseline corrected area under the insulin concentration time curve from 0 to 30 minutes after bolus administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCins(0-60min)</measure>
    <time_frame>60 minutes</time_frame>
    <description>Baseline corrected area under the insulin concentration time curve from 0 to 60 minutes after bolus administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCins(0-600min)</measure>
    <time_frame>600 minutes</time_frame>
    <description>Baseline corrected area under the insulin concentration time curve from 0 to 600 minutes after bolus administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax insulin</measure>
    <time_frame>10 hours</time_frame>
    <description>Maximum observed baseline corrected insulin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax insulin</measure>
    <time_frame>10 hours</time_frame>
    <description>Time from bolus administration to baseline corrected Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TmaxGIR</measure>
    <time_frame>10 hours</time_frame>
    <description>Time from bolus administration to maximum baseline corrected glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIRmax</measure>
    <time_frame>10 hours</time_frame>
    <description>Maximum baseline corrected glucose infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Number of Adverse Events in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical safety laboratory</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Haematology, biochemistry and urinalysis: changes and findings from Baseline in clinical safety laboratory parameters during the trial duration, from screening, and at follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Type1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>BioChaperone® insulin lispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of BioChaperone® insulin lispro</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fiasp®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single subcutaneous administration of Fiasp® (insulin aspart)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Novorapid®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single subcutaneous administration of Novorapid® (insulin aspart)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone® insulin lispro</intervention_name>
    <description>Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump</description>
    <arm_group_label>BioChaperone® insulin lispro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fiasp®</intervention_name>
    <description>Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump</description>
    <arm_group_label>Fiasp®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novorapid®</intervention_name>
    <description>Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump</description>
    <arm_group_label>Novorapid®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 Diabetes Mellitus for more than 12 months.

          -  BMI between 18.5 and 28.5 kg/m².

          -  HbA1C level &lt;=9.0%.

          -  Insulin treated for at least 12 months with total insulin dose &lt;1.2U/kg/day.

        Exclusion Criteria:

          -  Type 2 Diabetes Mellitus.

          -  History of multiple and/or severe allergies to drugs or foods.

          -  Any history or presence of clinically relevant cardiovascular, pulmonary, respiratory,
             gastrointestinal, hepatic, renal, metabolic, endocrinological (with the exception of
             conditions associated with diabetes mellitus), haematological, dermatological,
             neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynaecologic
             (if female), or infectious disease, or signs of acute illness as judged by the
             Investigator.

          -  More than one episode of severe hypoglycaemia with seizure, coma or requiring
             assistance of another person during the past 6 months.

          -  Proliferative retinopathy or maculopathy and/or severe neuropathy, in particular
             autonomic neuropathy.

          -  Females of childbearing potential, who are pregnant, breast-feeding or intend to
             become pregnant or are not using highly effective contraceptive methods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Klein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

